#RNA Interference (RNAi) Drug Delivery Market Scope | Explore Tumblr posts and blogs

soumyafwr · 9 months ago

Text

RNA Interference (RNAi) Drug Delivery Market Share, Overview, Competitive Analysis and Forecast 2031

#RNA Interference (RNAi) Drug Delivery Market #RNA Interference (RNAi) Drug Delivery Market Scope #RNA Interference (RNAi) Drug Delivery Market Report #RNA Interference (RNAi) Drug Delivery Market Research

0 notes

skyquest-market-research · 3 days ago

Text

Oligonucleotide Synthesis Market Outlook, Size, Growth Factors, and Forecast 2025-2032

Oligonucleotide synthesis market is experiencing rapid expansion, driven by increasing applications in genetic research, diagnostics, therapeutics, and drug discovery. As advancements in synthetic biology and molecular diagnostics continue to evolve, the demand for high-quality oligonucleotides is soaring. According to SkyQuest’s latest report on the Oligonucleotide Synthesis Market, Oligonucleotide Synthesis Market size is poised to grow at a CAGR of 17.4% by 2032, driven by technological innovations and rising research investments.

The oligonucleotide synthesis market plays a crucial role in genomics, molecular biology, and biotechnology. It encompasses the development of short DNA and RNA sequences that serve as essential tools for PCR, gene editing, and targeted therapeutics. With the increasing adoption of oligonucleotides in clinical applications, the market is projected to experience significant expansion in the coming years.

Request a sample of the report here: https://www.skyquestt.com/sample-request/oligonucleotide-synthesis-market

Key Market Drivers Shaping Oligonucleotide Synthesis Growth

Growing Demand for Personalized Medicine

The rise of precision medicine has fueled the demand for custom oligonucleotides. Researchers and pharmaceutical companies are increasingly leveraging oligonucleotides for targeted therapies, particularly in cancer treatment and rare genetic disorders.

Advancements in Gene Editing Technologies

Innovations in CRISPR, RNA interference (RNAi), and antisense oligonucleotides are expanding the scope of oligonucleotide-based therapies. These breakthroughs are transforming genetic research, enabling more precise and effective treatments.

Expanding Applications in Diagnostics

Oligonucleotide probes and primers are widely used in molecular diagnostics, particularly in PCR-based testing, next-generation sequencing (NGS), and microarrays. The increasing prevalence of infectious diseases and genetic disorders has driven the demand for oligonucleotide-based diagnostic solutions.

Increased Investment in Biotechnology Research

Pharmaceutical and biotech companies are investing heavily in oligonucleotide research, aiming to develop novel therapeutics and drug delivery mechanisms. Governments and private organizations are also providing funding to accelerate genetic research.

Speak with an analyst for in-depth market insights: https://www.skyquestt.com/speak-with-analyst/oligonucleotide-synthesis-market

Oligonucleotide Synthesis Market Segmentation:

By Product Type

Synthesized Oligonucleotides – Custom sequences used in research, diagnostics, and therapeutics

Reagents and Consumables – Essential materials for synthesis processes

Equipment – Automated synthesizers and analytical tools for high-throughput oligonucleotide production

By Application

Research & Development – Genomic studies, drug discovery, and synthetic biology

Diagnostics – PCR, NGS, and DNA microarrays

Therapeutics – Antisense oligonucleotides, siRNA, and mRNA-based therapies

By End-User

Biotechnology & Pharmaceutical Companies – Focused on drug development and clinical applications

Academic & Research Institutions – Conducting genomics and molecular biology studies

Contract Research Organizations (CROs) – Supporting large-scale oligonucleotide synthesis and testing

Oligonucleotide Synthesis Market Regional Insights

North America: Leading the Market with Strong Research Infrastructure

The United States and Canada dominate the oligonucleotide synthesis market, driven by strong research capabilities, robust funding, and a high concentration of biotechnology companies. The presence of key industry players and increasing clinical trials further contribute to regional growth.

Europe: Rising Investments in Genetic Research

Countries like Germany, the UK, and France are expanding their biotechnology sectors, investing in advanced gene therapy and diagnostic solutions. The European Union’s support for genomic research is fostering innovation in oligonucleotide applications.

Asia-Pacific: Fastest-Growing Market with Expanding Biotech Industry

China, Japan, and India are witnessing rapid market expansion due to increasing investments in genetic research, a growing pharmaceutical industry, and government support for biotechnological advancements. The demand for oligonucleotide-based diagnostics and therapies is significantly increasing in the region.

Latin America & Middle East: Emerging Markets with High Growth Potential

Countries in Latin America and the Middle East are gradually adopting oligonucleotide synthesis technologies, primarily in medical research and infectious disease diagnostics. Increasing healthcare investments are expected to drive market growth in these regions.

Buy the full report for comprehensive market analysis: https://www.skyquestt.com/buy-now/oligonucleotide-synthesis-market

Key Players in the Oligonucleotide Synthesis Market

Several major players dominate the oligonucleotide synthesis market, focusing on innovation, product development, and strategic collaborations. Key companies include:

Thermo Fisher Scientific

Agilent Technologies

Merck KGaA

Integrated DNA Technologies (IDT)

LGC Biosearch Technologies

Eurofins Genomics

GenScript Biotech Corporation

TriLink BioTechnologies

These companies are expanding their production capacities and investing in new technologies to meet the rising demand for synthetic oligonucleotides.

Emerging Trends and Technological Innovations

Automated High-Throughput Synthesis

The adoption of automated systems is improving efficiency, scalability, and precision in oligonucleotide production. Advanced synthesis platforms are enabling rapid turnaround times for research and clinical applications.

Expansion of RNA-Based Therapeutics

RNA-based drugs, including mRNA vaccines and RNAi therapies, are gaining significant traction. This trend is expected to drive the demand for oligonucleotide synthesis in pharmaceutical and biotech industries.

Sustainable and Cost-Effective Synthesis Methods

Researchers are developing green synthesis approaches to minimize environmental impact and reduce production costs, making oligonucleotide synthesis more sustainable.

The Future of the Oligonucleotide Synthesis Market

The oligonucleotide synthesis market is on an upward trajectory, driven by advancements in gene editing, diagnostics, and therapeutics. As personalized medicine gains momentum and biotechnology continues to evolve, the demand for high-quality oligonucleotides will continue to rise. Companies investing in automation, innovative research, and sustainable production methods are well-positioned for success in this rapidly growing industry.

For a detailed market analysis and strategic insights, explore the full SkyQuest report: https://www.skyquestt.com/report/oligonucleotide-synthesis-market

#Asia Oligonucleotide Synthesis Market #Europe Oligonucleotide Synthesis Market #Middle East Oligonucleotide Synthesis Market Size #North America Oligonucleotide Synthesis Market

0 notes

daisyri-me · 3 years ago

Text

Antisense & RNAi Therapeutics Market - Forecast to Grow at a CAGR of 8.6% During 2014-2025

Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Access Sample Report of this report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

The key players of Antisense & RNAi Therapeutics industry are Benitec Biopharma, GSK, Marina Biosciences, Sanofi-Genzyme, and Alnylam Pharmaceuticals. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

For More Information visit @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market

Market Segment:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025) • RNA Interference • siRNA • miRNA • Antisense RNA

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email:[email protected]

#antisense & rnai therapeutics market

0 notes

chitrakullkarni · 4 years ago

Text

Antisense & RNAi Therapeutics Market Technological Developments, Competitive Landscape and Strategic Initiatives

The global Antisense & RNAi Therapeutics Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.

Market Overview:

Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Key Players:

Olix Pharmaceuticals

GlaxoSmithKline Plc

Sanofi S.A.

Alnylam Pharmaceuticals

Isis Pharmaceuticals / Ionis Pharmaceuticals

Benitec Biopharma Ltd.

Acuitas Therapeutics

Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

Silence Therapeutics Plc

Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Growth Drivers:

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years.

Application Outlook:

Oncology

Cardiovascular

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

Pulmonary Delivery

Intravenous Injections

Intradermal Injections

Intraperitoneal Injections

Topical Delivery

Regional Outlook:

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

Browse Related Category Research Reports @ https://blog.naver.com/tomclark

0 notes

esglatestmarketnews · 4 years ago

Text

Antisense & RNAi Therapeutics Market Analysis And Key Business Strategies 2025

February 04, 2021: Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Request a Free Sample Copy of this Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market

The key players of Antisense & RNAi Therapeutics industry are Benitec Biopharma, GSK, Marina Biosciences, Sanofi-Genzyme, and Alnylam Pharmaceuticals. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Market Segment:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)

• RNA Interference

• siRNA

• miRNA

• Antisense RNA

Antisense & RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)

• Oncology

• Cardiovascular

• Respiratory Disorders

• Renal Diseases

• Neurodegenerative Disorders

• Genetic Disorders

• Infectious Diseases

• Other

Antisense & RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

• Pulmonary Delivery

• Intravenous Injections

• Intradermal Injections

• Intraperitoneal Injections

• Topical Delivery

• Other Delivery Methods

Antisense & RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America

• U.S.

• Canada

• Europe

• Germany

• U.K.

• Asia Pacific

• Japan

• China

• Latin America

• Brazil

• Middle East & Africa

• South Africa

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email: [email protected]

0 notes

newinnovationalmarketresearch · 4 years ago

Text

Antisense & RNAi Therapeutics Market 2025 Report by Global Key Players, Trends, Share, Industry Size, Segmentation

Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Market Synopsis of Antisense & RNAi Therapeutics Market:

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market

Table of Contents:-

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Antisense & RNAi Therapeutics: Market Variables, Trends & Scope

Chapter 4 Antisense & RNAi Therapeutics: Product Estimates & Trend Analysis

Chapter 5 Antisense & RNAi Therapeutics: Application Estimates & Trend Analysis

Chapter 6 Antisense & RNAi Therapeutics: End-use Estimates & Trend Analysis

Chapter 7 Antisense & RNAi Therapeutics: Industrial End-use Estimates & Trend Analysis

Chapter 8 Antisense & RNAi Therapeutics: Regional Estimates & Trend Analysis

Chapter 9 Competitive Landscape

Chapter 10 Antisense & RNAi Therapeutics: Manufacturers Company Profiles

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

0 notes

latestmarketreport · 5 years ago

Text

Antisense & RNAi Therapeutics Market Size | Business Opportunities & Future Trends | Forecast To 2028

San Francisco, CA - Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.

Request a PDF Sample @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth.

The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years.

Regional Analysis For Antisense & RNAi Therapeutics Market:

For comprehensive understanding of market dynamics, the global Antisense & RNAi Therapeutics Market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, Latin America and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Significant Features that are under Offering and Key Highlights of the Reports:

1 Detailed overview of Antisense & RNAi Therapeutics Market

2 Changing market dynamics of the industry

3 In-depth market segmentation by Type, Application etc

4 Historical, current and projected market size in terms of volume and value

5 Recent industry trends and developments

6 Competitive landscape of Antisense & RNAi Therapeutics Market

7 Strategies of key players and product offerings

8 Potential and niche segments/regions exhibiting promising growth.

For More Technical Insights, Download Brochure @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market

0 notes

marketanalysisdata · 4 years ago

Text

Antisense & RNAi Therapeutics Market Analysis of Industry Size, Research and Economic Growth Report by 2025

31st May 2021 – Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi).

Double-stranded RNA fragments initiate the RNAi process, and this double helix is the actual suppressor of its equivalent gene. The Antisense & RNAi Therapeutics Market is estimated to grow at a significant CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe. Growing occurrence of infectious diseases, coronary artery diseases, neurodegenerative diseases, and cardiac ailments, developed research and development sectors, and rising use of enhanced technology are documented as major factors of Antisense & RNAi Therapeutics industry that are estimated to enhance the growth in the years to come. However, toxicity of antisense and RNAi molecules-based drugs may restrain overall market growth in the coming years. Antisense & RNAi Therapeutics Market is segmented based on technology, mode of action, application, and region.

Access Antisense & RNAi Therapeutics Market Report with TOC @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market

Antisense RNA and RNA Interference are the enhanced technology used that could be explored in Antisense & RNAi Therapeutics in the forecast period. RNA interference includes miRNA and siRNA. RNA Interference technology accounted for the largest market share and is estimated to lead the overall market in the coming years. This may be because of advantages of the technology over antisense technology. The miRNA maintains the cells identity; whereas siRNA allows induction at enhanced stages of cancer growth. The mode of action comprises of topical delivery, pulmonary delivery, intraperitoneal injections, intravenous injections, intradermal injections, and others could be explored in Antisense & RNAi Therapeutics in the foremost period. The intravenous route sector accounts for the largest market share and is estimated to lead the overall market in the coming years. This may be because liver can be targeted easily by virtue of an intravenous and fast drug removal without anticipated pharmacological action.

The market may be categorized based on applications like infectious diseases, oncology, genetic disorders, cardiovascular, neurodegenerative disorders, respiratory disorders, renal diseases, and others. The oncology sector accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. Globally, North America accounted for the largest market share of Antisense & RNAi Therapeutics and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be growing number of clinical trials, government initiative for developing antisense therapeutics, developed research and development laboratories, and high investment by biotechnology industries for development of RNAi therapeutic. The United States is a major consumer of Antisense & RNAi Therapeutics in this region, as presence of key manufacturers in the region.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise government initiative toward R&D and various other forms of siRNA delivery techniques is a strong factor.

The key players of Antisense & RNAi Therapeutics industry are Benitec Biopharma, GSK, Marina Biosciences, Sanofi-Genzyme, and Alnylam Pharmaceuticals. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.

Request a Sample Copy of Antisense & RNAi Therapeutics Market Report @ https://www.millioninsights.com/industry-reports/antisense-rnai-therapeutics-market/request-sample

0 notes

latestmarketresearchtrends-blog · 4 years ago

Text

Antisense & RNAi Therapeutics Market Overview, Competitive Landscape and Forecasts 2025